Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome

International Journal of Colorectal Disease

Volumn 27, Issue 3, 2012, Pages 381-389

  Chua, Terence C ^a   Liauw, Winston ^a   Morris, David L ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Appendiceal neoplasm; Cytoreductive surgery; Intraperitoneal chemotherapy; Pseudomyxoma peritonei

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FRESH FROZEN PLASMA; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; MITOMYCIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PERITONEUM CANCER; PERITONEUM PSEUDOMYXOMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE; BLOOD; DISEASE FREE SURVIVAL; INFUSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEUM TUMOR; PLASMA; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD TRANSFUSION; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PLASMA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSEUDOMYXOMA PERITONEI; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84862607755     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1303-8     Document Type: Article

References (26)

1. Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69-76
2. Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12:585-603
3. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M (2008) Consensus statement on the loco-regional treatment of appendi-ceal mucinous neoplasms with peritoneal dissemination (pseudo-myxoma peritonei). J Surg Oncol 98:277-282
4. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O'Brien PC, van Heerden JA (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219:112-119
5. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241:300-308
6. Järvinen P, Järvinen HJ, Lepistö A (2010) Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis 12:868-872
7. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M (2009) Pseudomyxoma peritonei: biological features are the domi nant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 249:243-249
8. Sugarbaker PH (2009) Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 10:1965-1977
9. Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL (2010) Secondary Cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg 211:526-535
10. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudo-myxoma peritonei". Am J Surg Pathol 19:1390-1408
11. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL (2009) Long-term survival in patients with pseudo-myxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16:1903-1911
12. Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49-58
13. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29-42
14. Chua TC, Liauw W, Zhao J, Morris DL (2011) Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg 253(4):769-773
15. Farquharson AL, Pranesh N, Witham G, Swindell R, Taylor MB, Renehan AG, Rout S, Wilson MS, O'Dwyer ST, Saunders MP (2008) A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 99:591-596
16. Younes RN, Rogatko A, Brennan MF (1991) The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 213:107-113
17. Mikki C, Hiro J, Ojima E, Inoue Y, Mohri Y, Kusunoki M (2006) Perioperative allogenic blood transfusion, the related cytokine response and long-term survival after potentially curative resection of colorectal cancer. Clin Oncol (R Coll Radiol) 18:60-66
18. Ojima R, Iwashashi M, Nakamori M, Nakamura M, Naka T, Katsuda M, Iida T, Hayata K, Yamaue H (2009) Association of allogenic blood transfusion and long-term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg 13:1821-1830
19. Oefelein MG, Colangelo LA, Rademaker AW, McVary KT (1995) Intraoperative blood loss and prognosis in prostate cancer patients undergoing radical retropubic prostatectomy. J Urol 154:442-447
20. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi M, Mizuno S, Makuuchi M (1994) Perioperative blood transfusion promotes recurrence of hepatocel-lular carcinoma after hepatectomy. Surgery 115:303-309
21. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP (2009) Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249:617-623
22. van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA (2002) Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperther-mic intraperitoneal chemotherapy. Ann Surg Oncol 10:961-967
23. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M (2007) Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 14:2300-2308
24. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH (2004) Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87:162-166
25. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA (2007) Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol 14:493-499
26. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267-272